Join Aligos Therapeutics (#ALGS) for a virtual KOL event on Thurs. July 18 at 3pm ET featuring Mark Sulkowski, MD (Johns Hopkins University School of Medicine), who will join company management to review positive Phase 1b data from the ongoing ALG-000184 clinical study presented at #EASL2024. Register: https://bit.ly/3WrdZ5D
LifeSci Advisors, LLC’s Post
More Relevant Posts
-
Don't forget to register your attendance to the FREE Webinar with MarketOpen Australia that is being held tomorrow, Wednesday 24th July over Zoom. Dr Liz Dallimore will be providing an update on our Phase 2 clinical trial program. Learn more through the post below ⬇️ #AGN #ASX #stroke #clinicaltrial #strokeawareness #lifescience #investorupdate
Argenica Therapeutics Managing Director and CEO Dr Liz Dallimore will provide an update on the Company's Phase 2 clinical trial program in acute ischaemic stroke on Direct Connect webinar, Wednesday July 24 at 10:30am AWST / 12:30pm AEST. Dr Dallimore will also participate in a Q&A with shareholders post presentation. Registration is FREE and webinar is hosted on ZOOM: https://lnkd.in/gYTigpYF Stewart Walters Holly Walters Amanda Ellis Riley Maring Liddy McCall Bruno Meloni Meghan Thomas Emma Waldon #AGN #ArgenicaTherapeutics #Stroke #Phase2 #ClinicalTrial
To view or add a comment, sign in
-
SFA Therapeutics will be presenting at the BioFuture Conference, in NYC on October 5th at 10:45am Dr. Ira Spector, CEO, will be presenting the updated data from the extension to Cohort 1 of the ongoing Phase 1b clinical trial. The data are summarized below: 92% of patients showed PASI >50 improvement 71% of patients showed PASI >75 improvement 72% is mean PASI improvement in all subjects 87% is mean PASI improvement in subjects with PASI >75
To view or add a comment, sign in
-
-
We invite you to watch the latest US HAEA Treatment Education Webinar Brief: Astria's ALPHA-STAR Clinical Trial of potential therapy STAR-0215 with Chris Morabito, M.D., CMO at Astria Therapeutics. Learn more about available HAE treatments and/or clinical development efforts. Watch the webinar HERE: https://lnkd.in/gEAwgYeX #HAE #HAEA #WebinarBrief #HereditaryAngioedema
To view or add a comment, sign in
-
-
So looking forward to this meeting! Jam packed with great speakers and content. If you’re attending, please stop by and learn how Voximetry is blazing the dosimetry trail in Theranostics!#theranostics #dosimetry #precisionmedicine #precisiononcology
Today is the last day to save when you register to attend the 2023 SNMMI Therapeutics Conference, September 21-23, 2023, at the Marriott Baltimore Waterfront. Register by midnight and join the discussion on the future of personalized medicine: www.snmmi.org/tc2023.
To view or add a comment, sign in
-
-
Senior Associate Dean for Academic & Student Affairs at USC Alfred E. Mann School of Pharmacy and Pharmaceutical Sciences
Many people have seen the Calm app on T.V., but what do you know about the apps that are actually FDA cleared and require a prescription? Here is a brief review of those apps cleared for use in mental health disorders. #digitalhealth #pharmacy #USCMann
Dr. Kari Franson gives a brief overview of the importance of prescription digital therapies (PDTs), including some examples and why these therapies matter for both patients and clinicians. Watch the full presentation for by creating a free guest account! https://lnkd.in/eF-2iBvB Presented at the 2024 NEI Synapse, session titled "A New Script: Implementing Prescription Digital Therapeutics into Practice". Learn about upcoming NEI Meetings: https://lnkd.in/e_359k2J
Prescription Digital Therapies (PDTs)
To view or add a comment, sign in
-
GPCR Therapeutics is thrilled to announce a significant out-licensing agreement with Bridge Biotherapeutics, Inc. focused on the development and commercialization of a combination therapy involving our CXCR4-LPA1 inhibitor method, to aid our pursuit of innovative treatments for Idiopathic Pulmonary #Fibrosis (IPF). The scientific basis for this approach was recently published in the peer-reviewed journal 'Cell Communication and Signalling,' (https://lnkd.in/exTvdTxP) highlighting the potential of this innovative treatment for fibrotic diseases like IPF. We are excited about the prospects this collaboration brings and the opportunity to explore new avenues in IPF treatment alongside Bridge Biotherapeutics. IPF is a chronic lung condition causing scarring, making breathing progressively difficult. With no current treatment to halt or reverse scarring, our joint efforts aim to revolutionize IPF treatment and improve outcomes for patients. 📝 Read our press release: http://gpcr.co.kr/news/ 🔗 Learn more about our platform technology: https://lnkd.in/eH8YveC8 #BioTech #LungDisease #LungHealth
To view or add a comment, sign in
-
-
Struggling with the “Double-blinded placebo-controlled randomized controlled clinical trial for patients with Anal Intraepithelial Neoplasia (AIN),” Frantz Viral Therapeutics, a joint venture between Georgetown University Medical Center and Frantz Medical Group, faced numerous challenges while dealing with the trial phases. Moving ahead, they reached out to us with their concern over the ongoing challenges and sought help through Jeeva Clinical Trials Inc.'s eclinical solutions to accelerate their research. Learn how we accepted the challenges and, through our efficient and innovative solutions, assisted them in fulfilling their objectives from this case study: https://hubs.la/Q02gg2dj0 #RCT #clinicaltrials #AIN #healthtech #casestudy #randomizedclinicaltrial
To view or add a comment, sign in
-
-
Our CMO, Eric Harker MD MBA MPH is currently at #CHEST2023 to present results showing #bioequivalence and #concordance between unsupervised home spirometry and standard in-clinic spirometry in an Anagram Therapeutics, Inc.(formerly Synspira Therapeutics, Inc.) phase 2a clinical trial. These important findings further demonstrate that remote spirometry can be used to provide ample benefits to patients, healthcare providers, and #clinicaltrials. Check out the poster in detail here -https://lnkd.in/dX5hR2SK #decentralizedtrials #patientexperience #respiratory
To view or add a comment, sign in
-
-
We have officially dosed our first patient in the Zucara Therapeutics Inc. ZONE study. Grateful to be able to do such groundbreaking work for the #Type1Diabetes community as we attempt to eliminate #hypoglycemia. Dr. Alex Abitbol, who previously evaluated ZT-01 in a Phase 1b study and will be a principal investigator for ZONE, commented, "The positive results from the proof-of-concept Phase 1b study of ZT-01 were intriguing: in addition to observing a rise in glucagon, we also saw a corresponding rise in glucose during hypoglycemia. This suggests that ZT-01 can prevent nocturnal hypoglycemia, which is what we aim to confirm in the ZONE trial." Read more about this landmark study here: https://lnkd.in/gN48gNr5 #clinicalresearch #clinicaltrials #revolutionizingresearch
To view or add a comment, sign in
-
-
"Ongoing Clinical Trials of Nonviral siRNA Therapeutics" by Owen Fenton and co-authors provides a clinically centered perspective. One of its standout features is an exhaustive summary table detailing ongoing siRNA clinical trials, including indications of use, targets, and associated NCT numbers. Beyond this, the review illuminates the nuances of in vivo siRNA delivery, discussing innovations in sequence modification, ligand conjugation, and nanoparticle packaging. A must-read for understanding the present challenges and future potential of siRNA therapies. 👇 https://lnkd.in/etsChYiB #RNA #siRNA #ClinicalTrials #DrugDelivery
To view or add a comment, sign in